All Posts:health insurance

• Rise in Claim Denial Rates for Cancer-Related Advanced Genetic Testing

  A newly published analysis by Georgetown Lombardi member So-Yeon Kang, PhD, MBA, and colleagues has found that both the use of next-generation sequencing (NGS) testing for cancer and the rate of claim denials for such testing increased between 2016 and 2021, despite implementation of a recent Medicare national coverage determination that established coverage standards for NGS testing. Read more about this research.

  Category: News Release Tags: cancer, genetic testing, health insurance, Medicare, next generation sequencing testing